REG - BioPharma Credit PLC - UPDATES TO THE DISCOUNT CONTROL MECHANISM

Biopharma CreditAnnouncement

27/03/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240327:nRSa4217Ia&default-theme=true

RNS Number : 4217I  BioPharma Credit PLC  27 March 2024

BioPharma Credit PLC

27 March 2024

 

This announcement contains inside information as defined in the Market Abuse
Regulation No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR").

BIOPHARMA CREDIT PLC

(THE "COMPANY")

UPDATES TO THE DISCOUNT CONTROL MECHANISM

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor,
announces the following updates to its Discount Control Mechanism ("DCM")
following consultation with certain shareholders that hold, in the aggregate,
a majority of the Company's shares.

Under the current terms of the DCM, as originally described in the Company's
Prospectuses dated 1 March 2017 and 14 March 2018, and subsequently revised as
of 7 November 2022, if the shares of the Company trade at a discount greater
than 5 per cent. over a three-month period (the "First Trigger"), the Company
is required to apply up to 50 per cent. of proceeds from debt repayments in
purchasing Company shares until such time that the two-week discount is less
than 5 per cent. In addition, if the discount is greater than 10 per cent.
over a six-month period (the "Second Trigger"), the Company is required to
apply up to 100 per cent. of proceeds from debt repayments until such time
that the two-week discount is less than 5 per cent.

Currently, the Company continues to operate with the Second Trigger activated
and must therefore reserve the entirety of US$155 million to purchase shares,
which the Company has been pursuing at scale. During the first two months of
2024 the Company acquired approximately 49 million shares at a total cost of
US$46 million at an average price of US$0.93 yet the current discount remains
at 10.23%.

As previously announced on 15 March 2024, the Company was unable to
participate in the new additional US$100,000,000 senior secured loans to
UroGen Pharma, Inc. due to adherence with the DCM. The current coupon of the
foregone UroGen investment is SOFR + 7.25 per cent., or 12.80% at current SOFR
rates excluding additional fees payable upon drawing. Continued adherence to
the current formulation of the DCM will result in the Company being unable to
participate in any new investments until the DCM condition is satisfied.

While the Investment Manager and the Board firmly believe in the value of a
discount control mechanism, they also believe that being prevented from
deploying considerable available resources in any new investment opportunities
due in large part to adverse market conditions, is not in the best interest of
shareholders:

·    While the near-term accretion from share repurchases can be
attractive, this ignores the significant opportunity cost of foregoing new
investments with compelling return characteristics that would help the
continued diversification of the portfolio.

·    As a result of current market conditions for investment companies,
even large repurchases are having a limited impact on discounts to NAV.

·    Holding back cash to fund future repurchases, as opposed to investing
in new loans, has a material cash drag effect. Meanwhile funding new
investments using debt while holding significant cash is also not in the best
interest of the Company.

·    On 28 December 2023, 94.06% of the voting shareholders of the Company
voted in favor of approving the continuation of the Company's business as a
closed-ended investment trust.

Revised Terms of the DCM

As a result, the Investment Manager and the Board believe it is in the best
interest of the Company to update the DCM so as to provide for greater
flexibility as to when the Company can freely deploy capital:

·    The First Trigger will remain at a 5 per cent. discount to NAV and
the Company will be required to use up to US$25,000,000 in any given fiscal
year of the principal being returned to repurchase shares until such time that
the discount to NAV over a two-week period is less than 5 per cent.

·    The Second Trigger will remain at a 10 per cent discount to NAV and
the Company will be required to use up to US$50,000,000 in any given fiscal
year of the principal being returned to repurchase shares until such time that
the discount to NAV over a two-week period is less than 5 per cent.

·    For the remainder of calendar year 2024 the Company will be required
to use up to an additional US$50,000,000, on top of purchases made up to this
date, to repurchase shares until such time that the discount to NAV over a
two-week period is less than 5 per cent.

·    The Company may continue to repurchase shares in excess of the
abovementioned thresholds in its discretion based on the then current trading
price and volume in order to reduce the discount to NAV.

·    The Company will be free to use cash on hand in excess of the
aforementioned amounts to make new investments.

The Board will consider future changes to the DCM if it considers them to be
in the best interest of the Company and the shareholders. The Company intends
to continue to purchase shares opportunistically with available capital even
if the DCM triggers have not been reached. There will be no changes to the
requirement of the Investment Manager to use a portion of the proceeds earned
as incentive compensation to purchase shares under certain share price
scenarios.

 

Revised DCM language

If, in any 3 month rolling period, the Shares have, on average, traded at a
discount in excess of 5 per cent. to the Net Asset Value per Share (calculated
by comparing the middle market quotation of the Shares at the end of each
month in the relevant period to the prevailing published Net Asset Value per
Share (exclusive of any dividend declared) as at such month end and averaging
this comparative figure over the relevant period), the Company will, subject
to meeting its Target Dividend, use up to US$25,000,000 of the Company's
capital proceeds generated after the conclusion of such 3 month rolling period
in any fiscal year, to repurchase Shares at least until such time as the
Shares trade at an average discount of 5 per cent. or less to the Net Asset
Value per Share over a 2 week rolling period.

If, in any 6 month rolling period, the Shares have, on average, traded at a
discount in excess of 10 per cent. to the Net Asset Value per Share
(calculated by comparing the middle market quotation of the Shares at the end
of each month in the relevant period to the prevailing published Net Asset
Value per Share (exclusive of any dividend declared) as at such month end and
averaging this comparative figure over the relevant period), the Company will,
subject to meeting its Target Dividend, use up to US$50,000,000 of the
Company's capital proceeds generated after the conclusion of such 6 month
rolling period in any fiscal year, to repurchase Shares at least until such
time as the Shares trade at an average discount of 5 per cent. or less to the
Net Asset Value per Share over a 2 week rolling period.

Previous DCM language

If, in any 3 month rolling period, the Shares have, on average, traded at a
discount in excess of 5 per cent. to the Net Asset Value per Share (calculated
by comparing the middle market quotation of the Shares at the end of each
month in the relevant period to the prevailing published Net Asset Value per
Share (exclusive of any dividend declared) as at such month end and averaging
this comparative figure over the relevant period), the Company will, subject
to meeting its Target Dividend, use 50 per cent. of the Company's capital
proceeds generated after the conclusion of such 3 month rolling period, to
repurchase Shares at least until such time as the Shares trade at an average
discount of 5 per cent. or less to the Net Asset Value per Share over a 2 week
rolling period.

If, in any 6 month rolling period, the Shares have, on average, traded at a
discount in excess of 10 per cent. to the Net Asset Value per Share
(calculated by comparing the middle market quotation of the Shares at the end
of each month in the relevant period to the prevailing published Net Asset
Value per Share (exclusive of any dividend declared) as at such month end and
averaging this comparative figure over the relevant period), the Company will,
subject to meeting its Target Dividend, use 100 per cent. of the Company's
capital proceeds generated after the conclusion of such 6 month rolling
period, to repurchase Shares at least until such time as the Shares trade at
an average discount of 5 per cent. or less to the Net Asset Value per Share
over a 2 week rolling period.

 

Enquiries

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. The Company seeks to
provide long-term shareholder returns, principally in the form of sustainable
income distributions from exposure to the life sciences industry. The Company
seeks to achieve this objective primarily through investments in debt assets
secured by royalties or other cash flows derived from the sales of approved
life sciences products.

 

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUNRURSOUOUUR